MedPage Today

Drug for Sexual Desire Disorder in Women Works in Men, Too

SAN ANTONIO -- A drug approved for hypoactive sexual desire disorder (HSDD) in premenopausal women also improved sexual dysfunction in some men, according to a small dataset reported here. Among 19 ...
Business Insider

Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment

~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated ...
Seeking Alpha

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5i treatment Data from this Phase 2 clinical study is expected by end of calendar year 2024 ...